The U.S. Food and Drug Administration has delayed indefinitely making a decision on whether the emergency contraceptive Plan B should be sold over the counter, prompting the resignation of Susan Wood, the agency's director of women's health.
Former FDA Advisory Committee members discuss the debate over Plan B. Are there legitimate safety concerns or has ideology trumped science, as some critics claim?
Alastair J.J. Wood, professor of medicine and pharmacology at Vanderbilt University School of Medicine in Nashville, Tenn.
Vivian Lewis, M.D., professor, obstetrics and gynecology director, Division of Reproductive Endocrinology at the University of Rochester Medical Center in New York
W. David Hager, professor and consultant on infectious diseases in obstetrics and gynecology, Division of General Obstetrics and Gynecology at the University of Kentucky College of Medicine; director of the University of Kentucky Affiliated Residency Training Program in Obstetrics and Gynecology at Central Baptist Hospital; practicing obstetrician and gynecologist at Women's Care Center in Lexington, Ky.